Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label single center pilot study investigating the clinical response and mechanism of action of infliximab in the treatment of adults with inflammatory bowel disease who have moderate to severe pyoderma gangrenosum

Next Previous
Trial Profile

An open label single center pilot study investigating the clinical response and mechanism of action of infliximab in the treatment of adults with inflammatory bowel disease who have moderate to severe pyoderma gangrenosum

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Pyoderma gangrenosum; Ulcerative colitis
  • Focus Therapeutic Use

Most Recent Events

  • 23 Jun 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
  • 23 Jun 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
  • 15 Oct 2009 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top